Cocrystal Pharma Plans To Extend Phase 2a Influenza Challenge Study With Oral PB2 Inhibitor CC-42344 Due To Low Influenza Infection Among Challenged Participants
Cocrystal Pharma Plans To Extend Phase 2a Influenza Challenge Study With Oral PB2 Inhibitor CC-42344 Due To Low Influenza Infection Among Challenged Participants
Cocrystal Pharma计划由于参与者中流感感染率低，延长口服PB2抑制剂CC-42344的第2a阶段流感挑战研究。
"While CC-42344 showed a favorable safety and tolerability profile, we're disappointed by the low infectivity rate of the challenge influenza strain used in this study. The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules. The low infectivity obtained in this study hindered antiviral data analysis," said Sam Lee, Ph.D., Cocrystal's President and co-CEO.
"虽然CC-42344展现了良好的安全性和耐受性，但我们对本研究中使用的挑战性流感毒株的低传染率感到失望。建立健康、未感染研究对象的稳健流感感染对于判断评估抗病毒分子的临床终点至关重要。本研究中获得的低传染性阻碍了抗病毒数据的分析，" Cocrystal的总裁兼联席首席执行官Sam Lee博士说道。